AYTU
Income statement / Annual
Last year (2026), Aytu BioPharma Inc's total revenue was $57.57 M,
a decrease of 13.27% from the previous year.
In 2026, Aytu BioPharma Inc's net income was -$14.25 M.
See Aytu BioPharma Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2026
|
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
06/30/2026 |
06/30/2025 |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
| Operating Revenue |
$57.57 M |
$66.38 M |
$65.18 M |
$107.40 M |
$96.67 M |
$65.63 M |
$27.63 M |
$7.32 M |
$3.66 M |
$3.22 M |
| Cost of Revenue |
$20.75 M
|
$20.55 M
|
$16.13 M
|
$40.77 M
|
$46.39 M
|
$36.43 M
|
$8.28 M
|
$2.20 M
|
$2.05 M
|
$1.42 M
|
| Gross Profit |
$36.82 M
|
$45.83 M
|
$49.05 M
|
$66.63 M
|
$50.28 M
|
$29.20 M
|
$19.35 M
|
$5.12 M
|
$1.61 M
|
$1.80 M
|
| Gross Profit Ratio |
0.64
|
0.69
|
0.75
|
0.62
|
0.52
|
0.44
|
0.7
|
0.7
|
0.44
|
0.56
|
| Research and Development Expenses |
$0.00
|
$1.33 M
|
$2.77 M
|
$4.10 M
|
$12.66 M
|
$5.62 M
|
$1.72 M
|
$589.07 K
|
$167.60 K
|
$1.35 M
|
| General & Administrative Expenses |
$19.27 M
|
$17.38 M
|
$19.95 M
|
$28.63 M
|
$31.17 M
|
$25.50 M
|
$19.66 M
|
$0.00
|
$17.73 M
|
$17.61 M
|
| Selling & Marketing Expenses |
$23.37 M
|
$20.91 M
|
$22.08 M
|
$41.45 M
|
$38.71 M
|
$30.31 M
|
$11.40 M
|
$0.00
|
$0.00
|
-$242.00
|
| Selling, General & Administrative Expenses |
$42.64 M
|
$38.29 M
|
$42.04 M
|
$70.08 M
|
$69.88 M
|
$55.81 M
|
$31.06 M
|
$19.24 M
|
$17.73 M
|
$17.61 M
|
| Other Expenses |
$2.49 M
|
$14.05 M
|
$5.84 M
|
$9.52 M
|
$77.65 M
|
$26.64 M
|
$7.70 M
|
$2.14 M
|
$6.28 M
|
$1.71 M
|
| Operating Expenses |
$45.13 M
|
$53.66 M
|
$50.65 M
|
$83.70 M
|
$160.19 M
|
$88.07 M
|
$40.48 M
|
$21.96 M
|
$19.45 M
|
$20.66 M
|
| Cost And Expenses |
$65.89 M
|
$74.21 M
|
$66.77 M
|
$124.46 M
|
$206.58 M
|
$124.50 M
|
$48.76 M
|
$24.17 M
|
$21.50 M
|
$22.08 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$14.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
-$1.90 M
|
$3.70 M
|
$4.79 M
|
$4.96 M
|
$147.50 M
|
$0.00
|
$0.00
|
$0.00
|
$749.42 K
|
$2.53 M
|
| Depreciation & Amortization |
$3.93 M
|
$5.38 M
|
$6.73 M
|
$8.82 M
|
$10.15 M
|
$9.20 M
|
$5.71 M
|
$2.73 M
|
$2.59 M
|
$4.36 M
|
| EBITDA |
-$4.38 M |
-$4.67 M |
$1.41 M |
-$3.27 M |
-$27.96 M |
-$29.04 M |
-$12.21 M |
-$14.12 M |
-$15.25 M |
-$15.61 M |
| EBITDA Ratio |
-0.08
|
-0.07
|
0.02
|
-0.03
|
-0.29
|
-0.44
|
-0.44
|
-1.93
|
-4.17
|
-4.85
|
| Operating Income Ratio |
-0.14
|
-0.12
|
-0.02
|
-0.16
|
-1.14
|
-0.9
|
-0.76
|
-2.3
|
-5.38
|
-6.25
|
| Total Other Income/Expenses Net |
-$5.92 M
|
-$5.92 M
|
-$8.79 M
|
$14.00 K
|
$1.02 M
|
$840.00 K
|
$7.51 M
|
-$10.29 M
|
$9.51 M
|
-$2.38 M
|
| Income Before Tax |
-$14.23 M
|
-$13.75 M
|
-$10.38 M
|
-$17.05 M
|
-$108.89 M
|
-$58.03 M
|
-$13.62 M
|
-$27.13 M
|
-$10.19 M
|
-$22.51 M
|
| Income Before Tax Ratio |
-0.25
|
-0.21
|
-0.16
|
-0.16
|
-1.13
|
-0.88
|
-0.49
|
-3.71
|
-2.78
|
-6.99
|
| Income Tax Expense |
-$21.00 K
|
$437.00 K
|
$2.14 M
|
$0.00
|
-$110.00 K
|
$259.00 K
|
$0.00
|
$20.04 M
|
$0.00
|
$0.00
|
| Net Income |
-$14.25 M
|
-$13.56 M
|
-$15.84 M
|
-$17.05 M
|
-$108.78 M
|
-$58.29 M
|
-$13.62 M
|
-$47.17 M
|
-$10.19 M
|
-$22.51 M
|
| Net Income Ratio |
-0.25
|
-0.2
|
-0.24
|
-0.16
|
-1.13
|
-0.89
|
-0.49
|
-6.44
|
-2.78
|
-6.99
|
| EPS |
-1.16 |
-2.16 |
-2.86 |
-5.11 |
-74.01 |
-69.6 |
-60.2 |
-1210.28 |
-3061.23 |
-193194.38 |
| EPS Diluted |
-1.16 |
-2.16 |
-2.86 |
-5.11 |
-74.01 |
-69.6 |
-60.2 |
-1210.28 |
-3061.23 |
-193194.38 |
| Weighted Average Shares Out |
$12.32 M
|
$6.28 M
|
$5.54 M
|
$3.34 M
|
$1.47 M
|
$840.00 K
|
$230.00 K
|
$38.97 K
|
$3.33 K
|
$117.00
|
| Weighted Average Shares Out Diluted |
$12.32 M
|
$6.28 M
|
$5.54 M
|
$3.34 M
|
$1.47 M
|
$840.00 K
|
$230.00 K
|
$38.97 K
|
$3.33 K
|
$117.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
